ESTRO 36 Abstract Book

743 / 1082

S727 ESTRO 36 2017
_______________________________________________________________________________________________
mean PTV Boost (SD, range) HI was 0.08 (0.02; 0.05-0.11)
and 0.07 (0.03; 0.05-0.12) (p=0.31) respectively.
No statistically significant difference in target volume
coverage or dose to rectum, other bowel or bladder
outside PTVBoost was seen between the two plans. Table
below summaries the dosimteric outcomes.
Conclusion
SIB delivery was achieved with comparable target and
normal tissue constraints for both techniques. VMAT
faster delivery times are likely to mean it is favoured for
this group of patients both because of reduction in intra-
fraction organ filling opportunity and departmental
throughput.
References
1. Huddart RA, Hall E, Hussain SA, Jenkins P, Rawlings C,
Tremlett J, Crundwell M, Adab FA, Sheehan D, Syndikus I
et al: Randomized noninferiority trial of reduced high-
dose volume versus standard volume radiation therapy for
muscle-invasive bladder cancer: results of the BC2001 trial
(CRUK/01/004). Int J Radiat Oncol Biol Phys 2013,
87(2):261-269
2. Cowan RA, McBain CA, Ryder WD, Wylie JP, Logue JP,
Turner SL, Van der Voet J, Collins CD, Khoo VS, Read GR:
Radiotherapy for muscle-invasive carcinoma of the
bladder: results of a randomized trial comparing
conventional whole bladder with dose-escalated partial
bladder radiotherapy. Int J Radiat Oncol Biol Phys 2004,
59(1):197-207.
Acknowledgments We acknowledge NHS funding to the
NIHR Biomedical Research Centre for Cancer and to Cancer
Research UK (CRUK).
Electronic Poster: Clinical track: Skin cancer / malignant
melanoma
EP-1371 Primary oesophageal melanoma responds to
hypofractionated radiotherapy
K. Griffin1, A. Scarsbrook 2, W. Merchant1, G.
Radhakrishna3, O. Donnelly3
1 St James' Institute of Oncology, Pathology, Leeds,
United Kingdom
2 St James' Institute of Oncology, Radiology, Leeds,
United Kingdom
3 St James' Institute of Oncology, Oncology, Leeds, United
Kingdom
Purpose or Objective
Oesophageal melanoma is rare; current practice would be
to consider surgical treatment first, with radiotherapy
reserved for unresectable or patients not suitable for
oesophagectomy. We report our experience of three
consecutive patients who responded to high-dose
hypofractionated radiotherapy to localised oesophageal
melanoma primaries.
Material and Methods
Each patient had endoscopic biopsy confirming primary
oesophageal melanoma. Prior to treatment whole-body
PET scans were performed to aid tumour localisation and
exclude nodal or distant metastases. PET scans were
repeated after completion of radiotherapy and patients
were followed-up clinically thereafter. Each patient gave
written consent for publication.
Two patients (A&B) received 50 Gy in 16 daily fractions
using a 3D conformal technique. The third patient (C)
received 30 Gy in 10 daily fractions followed by
intraluminal brachytherapy (16 Gy in 2 treatments, one
week apart).
Results
In all three cases tumours were Braf wildtype, PET-avid on
pre-treatment scans and no distant or nodal metastases
were identified.
All three patients developed odynophagia requiring
analgesia during and for several weeks following
treatment and lost weight, though no patient required
admission or enteral feeding support.
On post-treatment PET scans all patients had a response
in the oesophageal primary;
Patient A had a complete response. She remained disease-
free, with normal swallowing, until she died due to
myocardial infarction, 30 months after diagnosis (26
months since completion of treatment).
B had a good partial response; pretreatment 6 cm tumour
with SUVmax 20.8 - following treatment 2.8 cm,SUVmax
9.7. His swallowing remained normal without further
intervention until 24 months after diagnosis (22 months
after treatment) - at which point he reported mild
dysphagia and a further endoscopy identified residual
melanoma. He remains stent-free.
C had complete response of the primary oesophageal
melanoma but the post-treatment PET identified
metastatic disease in both lungs and peritoneal cavity. She
died 12 months after diagnosis (9 months after
treatment).
Conclusion
Oesophageal primaries are a rare site for non-cutaneous
melanomas with little evidence to guide management.
Based on our series tumours are FDG-avid and PET-CT is
likely to be useful in planning treatment.
Hypofractionated radiotherapy appears to be effective in
achieving local control and should be considered an
alternative to surgery for melanoma arising in the
oesophagus.
EP-1372 Preliminar results of fractionated cyberknife
stereotactic radiotherapy for uveal melanoma.
I. Bossi Zanetti1, M. Pellegrini2, G. Beltramo1, V. Ravera2,
A. Bergantin1, A.S. Martinotti1, I. Redaelli1, P. Bonfanti1,